Placental transfer of rosiglitazone in the first trimester of human pregnancy.
OBJECTIVE
To determine the degree of placental transfer of rosiglitazone in early human pregnancy.


METHODS
Prospective observational study.


METHODS
University teaching hospital.


METHODS
Thirty-one women undergoing surgical termination of pregnancy between 8 and 12 weeks' gestation.


METHODS
Each woman was given two doses of rosiglitazone (4 mg) before the procedure.


METHODS
Rosiglitazone concentration in fetal tissue and coelomic and amniotic fluids.


RESULTS
The mean maternal serum rosiglitazone concentration was 110.3 +/- 47.9 ng/mL. Rosiglitazone was detectable in 19 fetal samples (61.3%). The mean fetal tissue concentration was 52.7 +/- 26.3 ng/g. Rosiglitazone was more likely to be detected in fetal tissue if the gestation at termination was 10 weeks or more compared with earlier gestation. Coelomic fluid was obtained in 22 cases, and rosiglitazone was detected in 13 samples (59.1%). The mean concentration was 22.8 +/- 7.0 ng/mL. Rosiglitazone was detectable in only two of the 31 amniotic fluid samples, with concentrations of 10.3 and 12.6 ng/mL.


CONCLUSIONS
The risk of placental transfer of rosiglitazone is much higher at or after 10 weeks of gestation. Absence of detectable rosiglitazone in amniotic fluid despite its presence in fetal tissue suggests that fetuses may have the ability to metabolize rosiglitazone, and little parent drug was excreted unchanged in urine.
Chan
Louis Yik-Si
LY
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. lyschan@cuhk.edu.hk
Yeung
John Hok-keung
JH
Lau
Tze Kin
TK
D000028:Abortion, Induced; D000653:Amniotic Fluid / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics* / Q000652:urine; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011446:Prospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000493:pharmacokinetics* / Q000652:urine
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone